Bruker Corporation BRKR

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Con 16 acciones de BRKR (USD 1.025,60) habrías recibido USD 3,20 en dividendos en los últimos 12 meses.

• Zacks Investment Research 5 oct

  Are Options Traders Betting on a Big Move in Bruker Stock?

  Bruker Corporation (BRKR) is experiencing elevated implied volatility in its December 2026 $75 put options, suggesting traders expect significant price movement. However, the fundamental outlook remains weak, with analysts downgrading estimates over the past 60 days, pushing the consensus estimate down from 55 cents to 42 cents per share. The stock holds a Zacks Rank #3 (Hold) rating.

  

• Zacks Investment Research 2 oct

  Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term

  Bruker Corporation (BRKR), a life science and materials research systems manufacturer, is highlighted as a momentum investment opportunity despite holding a #3 (Hold) Zacks Rank. The stock has gained 4.3% over the past four weeks and features strong Momentum and VGM Style Scores of A and B respectively. One analyst raised earnings estimates for fiscal 2026, with the consensus estimate at $2.12 per share and an average earnings surprise of +22.7%.

  

• GlobeNewswire Inc. 22 sept

  Automated Microscopy Market Advances as AI-Powered Image Analysis Transforms Digital Pathology and Semiconductor Inspection

  The global Automated Microscopy Market is projected to reach USD 16.63 billion by 2035, growing at 7.35% CAGR, driven by AI-enabled image analysis, whole-slide digital pathology, and expanding applications in life sciences and semiconductor inspection. The U.S. market is expected to reach USD 5.19 billion by 2035 at 7.1% CAGR, while Asia Pacific is the fastest-growing region at 9.8% CAGR. Software is the fastest-growing segment, with electron microscopy emerging as the fastest-growing type.

  

• GlobeNewswire Inc. 22 sept

  Global Metabolomics Market to Reach US$9.01 Billion by 2035 as Precision Medicine, Biomarker Discovery and Advanced Analytics Unlock New Opportunities

  The global metabolomics market is projected to grow from USD 2.81 billion in 2025 to USD 9.01 billion by 2035, expanding at a CAGR of 12.36%. Growth is driven by precision medicine, biomarker discovery, and multiomics adoption, with oncology accounting for over 44% of the market. However, Q1 2026 faced challenges from geopolitical tensions, supply chain disruptions, and elevated logistics costs affecting laboratory budgets and procurement timelines.

  

• GlobeNewswire Inc. 17 jul

  Mass Spectrometry Market Size Worth USD 14.09 Billion by 2035 | SNS Insider

  The global mass spectrometry market is valued at $6.68 billion in 2025 and is projected to reach $14.09 billion by 2035, growing at a CAGR of 7.74%. Growth is driven by pharmaceutical manufacturing, omics research, clinical diagnostics, and precision medicine adoption. North America leads the market while Asia Pacific records the fastest growth at 9.12% CAGR.